Palisade Bio Faces Nasdaq Delisting Warning
Ticker: PALI · Form: 8-K · Filed: Mar 27, 2024 · CIK: 1357459
| Field | Detail |
|---|---|
| Company | Palisade Bio, Inc. (PALI) |
| Form Type | 8-K |
| Filed Date | Mar 27, 2024 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.01 |
| Sentiment | neutral |
Sentiment: neutral
Topics: listing-rule-violation, delisting-risk, compliance
Related Tickers: PBIO
TL;DR
Nasdaq's threatening to kick PBIO off the exchange, but they've got until Sept to fix it.
AI Summary
Palisade Bio, Inc. announced on March 27, 2024, that it received a determination letter from The Nasdaq Stock Market LLC on March 22, 2024, indicating non-compliance with listing rules. The company has been granted until September 18, 2024, to regain compliance.
Why It Matters
This filing signals potential delisting from Nasdaq, which could significantly impact the company's stock liquidity and investor confidence.
Risk Assessment
Risk Level: medium — The company is at risk of being delisted from Nasdaq, which could negatively impact its stock price and liquidity.
Key Numbers
- September 18, 2024 — Compliance Deadline (The date by which Palisade Bio must regain compliance with Nasdaq listing rules.)
Key Players & Entities
- Palisade Bio, Inc. (company) — Registrant
- The Nasdaq Stock Market LLC (company) — Listing Exchange
- March 27, 2024 (date) — Report Date
- March 22, 2024 (date) — Date of Determination Letter
- September 18, 2024 (date) — Deadline to Regain Compliance
FAQ
What specific Nasdaq listing rules has Palisade Bio failed to meet?
The filing does not specify the exact listing rules that Palisade Bio has failed to meet, only that a determination letter was received indicating non-compliance.
What actions is Palisade Bio taking to regain compliance with Nasdaq listing rules?
The filing does not detail the specific actions the company plans to take, but states they have been granted an exception period to regain compliance.
What is the previous name of Palisade Bio, Inc.?
Palisade Bio, Inc. was formerly known as Seneca Biopharma, Inc. (name change effective January 27, 2020) and prior to that, Neuralstem, Inc. (name change effective March 24, 2006).
What is the company's primary business according to its SIC code?
The company's Standard Industrial Classification (SIC) code is 2836, which corresponds to Biological Products (No Diagnostic Substances).
When was this 8-K filing submitted?
This 8-K filing was submitted on March 27, 2024.
Filing Stats: 927 words · 4 min read · ~3 pages · Grade level 11.7 · Accepted 2024-03-27 16:45:35
Key Financial Figures
- $0.01 — ch registered Common Stock, par value $0.01 per share PALI Nasdaq Capital Mark
Filing Documents
- form8-k.htm (8-K) — 49KB
- ex99-01.htm (EX-99.01) — 77KB
- ex99-01_001.jpg (GRAPHIC) — 2KB
- 0001493152-24-011527.txt ( ) — 311KB
- pali-20240327.xsd (EX-101.SCH) — 3KB
- pali-20240327_lab.xml (EX-101.LAB) — 33KB
- pali-20240327_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report on Form 8-K to be signed on its behalf by the undersigned hereunto duly authorized. Date: March 27, 2024 Palisade Bio, Inc. /s/ J.D. Finley By: J.D. Finley Chief Executive Officer